Pat Lawman, PhD

Scientific Advisor 

Patricia (Pat) Lawman, PhD, is currently a life sciences team member at Exchange Listing, LLC. Prior to consulting with Exchange Listing, Dr. Lawman co-founded and served as Chief Executive Officer (from 2003 to 2021) of Morphogenesis, Inc., a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. During her tenure at Morphogenesis, the Company raised over $38,000,000 in investments and non-dilutive funding and advanced from an R&D stage company to seeing its lead candidate in pivotal clinical trials. Recently, Morphogenesis was rebranded as Tuhura BioSciences. Dr Lawman also co-founded and was Chief Executive Officer of Veterinary Oncology Services, the first company in the world to offer personalized cancer vaccine production for companion animals. Prior to Morphogenesis, Dr. Lawman was first a Senior Research Scientist and then Division Director of Cancer Molecular Biology at the Walt Disney Memorial Cancer Institute, where she coordinated the multifaceted molecular biology, gene targeting, gene therapy, gene delivery, and universal stem cell projects, which she initiated. Pat holds Baccalaureate, Master’s, and Doctor of Philosophy degrees from the University of Florida where she was a Ford Foundation Pre-Doctoral Fellow in Anthropology, Plant Pathology, Immunology, and Medical Microbiology with specialties in Hematology and Oncology and has held faculty positions at both the University of Central Florida and the University of South Florida. Dr. Lawman has authored multiple publications and is a named inventor on numerous U.S. and worldwide patents.